UNICREDIT BANK/CALL/NOVO-NORDISK B/1300/0.1/18.06.25 | Real-time BOERSE MUENCHEN 12:46:13 31/05/2024 BST | ||
| 0.57 EUR | +1.79% |
|
| Current month | -9.68% | ||
| 1 month | -9.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 0.57 | +1.79% |
| 30/05/24 | 0.56 | +5.66% |
| 29/05/24 | 0.53 | -3.64% |
| 28/05/24 | 0.55 | -3.51% |
| 27/05/24 | 0.57 | -6.56% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 12:46 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HD1QYL |
| ISIN | DE000HD1QYL8 |
| Date issued | 08/01/2024 |
| Strike | 1,300 kr |
| Maturity | 18/06/2025 (383 Days) |
| Parity | 10 : 1 |
| Emission price | 0.38 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.88 € |
|---|---|
| Lowest since issue | 0.25 € |
| Spread | 0.01 € |
| Spread % | 1.72% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
916.9
DKK
Average target price
917.2
DKK
Spread / Average Target
+0.04%
- Stock Market
- Warrants
- Warrant
